Skip to main content

Effect of magnesium on prophylaxis of vasospasm, morbidity, and mortality in subarachnoid hemorrhage patients

Introduction

We propose this study in order to reach two end points: (a) vasospasm clinical incidence, confirmed by CT; and (b) the mortality of these patients in 28 days. The study shows a comparison of a group of patients that used Mg (Intervention Group 1) from those that did not (Control Group 2).

Methods

After institutional approval and informed consent, a prospective, randomized, nonblind study was performed between February and November 2008. The main goal of the study was to achieve a Mg serum concentration from 2.5 to 3.5 mg/dl, using a solution of Mg 2% (SG 5% 400 ml + MgSO4 10% 100 ml/24 hours), during the first 14 days of aneurysm rupture. Admission criteria: patients diagnosed with SAH and Δt <96 hours. Exclusion criteria: patients with SAH and Δt >96 hours.

Results

In a previous study evaluation we analysed a total of 56 patients, with 26 in Group 1 and 30 in Group 2 (Tables 1 and 2). Main results: Group 1 – vasospasm frequency 26.9% (n = 7) and mortality 19.2% (n = 5) in 28 days; Group 2 – vasospasm frequency 46.7% (n = 14) and mortality 33.3% (n = 10) in 28 days.

Table 1 (abstract P54)
Table 2 (abstract P54)

Conclusion

According to the outcome, we can conclude that Group 1 obtained a greater protection for vasospasm incidence and a decrease of mortality in comparison with Group 2. The P value was not significant due to a still small number of patients.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Macedo, S., Nuss, R., Pereira, S. et al. Effect of magnesium on prophylaxis of vasospasm, morbidity, and mortality in subarachnoid hemorrhage patients. Crit Care 13, P54 (2009). https://doi.org/10.1186/cc7856

Download citation

Keywords

  • Intervention Group
  • Magnesium
  • Informed Consent
  • Exclusion Criterion
  • Serum Concentration